Prognostic assessment of 1310 patients with non–small-cell lung cancer who underwent complete resection from 1980 to 1993

Inoue, Kentarou; Sato, Masami; Fujimura, Shigefumi; Sakurada, Akira; Takahashi, Satoshi; Usuda, Katsuo; Kondo, Takashi; Tanita, Tatsuo; Handa, Masashi; Saito, Yasuki; Sagawa, Motoyasu

doi:10.1016/s0022-5223(98)70006-6

Cited by 107 publications

(62 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 1997 system has been reported to have no significant difference between stages IB and IIA in many reports. [16][17][18][19][20][21][22] The 5-year survival rate of patients with stage IB disease is inferior to that of patients with stage IIA disease in our series according to the 1997 system. Prognosis in stage IIA has not been evaluated properly because of small number of the patients.…”

Section: Discussioncontrasting

confidence: 61%

“…Prognosis in stage IIA has not been evaluated properly because of small number of the patients. [16][17][18][19][20][21][22] The proportion of patients with stage IIA disease in our series increases from 2.5% to 9.5% in the 2009 system, and the 5-year survival rate of patients with stage IB disease is slightly superior to that of patients with stage IIA disease, but there is no difference between stages IB and IIA. Similar results are reported in another report.…”

Section: Discussionmentioning

confidence: 51%

See 1 more Smart Citation

Unification of T2a and T2b Tumors to T2 Tumors in Non-Small Cell Lung Cancer Staging

Haraguchi

Koizumi

Akiyama

et al. 2011

ATCS

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 61%

Section: Discussionmentioning

confidence: 51%

Unification of T2a and T2b Tumors to T2 Tumors in Non-Small Cell Lung Cancer Staging

Haraguchi

Koizumi

Akiyama

et al. 2011

ATCS

View full text Add to dashboard Cite

“…In the U.S. it kills more people than colon, breast, and prostate cancer combined and more women than breast cancer (Fig. 1) [3].For lung cancer, the staging system is based on differences in lung cancer survival [4,5]. The curability rate, as estimated by the 10-year survival rate for stage I disease, is high, particularly when the cancer diameter is Յ10 mm [6] (Fig.…”

mentioning

confidence: 99%

CT Screening for Lung Cancer: Update 2007

Henschke

Yankelevitz

2008

The Oncologist

View full text Add to dashboard Cite

Screening is the pursuit of the early diagnosis of cancer before symptoms occur. The purpose of early diagnosis is to provide early treatment, which potentially prevents death from the cancer. The usefulness of screening depends on how early the cancer can be diagnosed and how many deaths can be prevented by early treatment as compared with later symptom-prompted diagnosis and treatment.The goal of the Early Lung Cancer Action Project investigators was to develop an efficient methodology that would provide an ever-accumulating, continually updated body of evidence for evaluation of emerging new technologies for screening for cancer. This methodology recognizes that screening is a sequential process that starts with the pursuit of the early diagnosis of cancer followed by early treatment. It also recognizes that diagnostic research is fundamentally different from treatment research. To fully understand the current discussions on the evidence for lung cancer screening, key definitions are provided, including the differentiation between the first, baseline round of screening and all subsequent rounds of repeat screening and baseline and repeat cancers and their distribution by cell type. These definitions are critical in analyzing the results of various screening reports as they are not used by all.To provide optimal screening, a regimen for the diagnostic workup must be specified starting with the definition of the initial test, its positive result, and the workup for a positive result leading to a diagnosis of cancer. Assessment of diagnostic performance does not require a control group, but does require confirmation of the diagnosis.For assessment of the effectiveness of early treatment, a comparison group is needed. The comparison group may be formed by randomly assigning people with screen-diagnosed lung cancer to immediate or delayed treatment, as has been done for prostate cancer. This provides a direct assessment of any potential overdiagnosis of the cancer resulting from screening. Alternatively, a quasiexperimental control group can be used KEY CONCEPTS AND DEFINITIONSScreening has been defined as the pursuit of the early diagnosis of cancer before symptoms occur. The purpose of early diagnosis is to provide early treatment, which potentially prevents death from the cancer. The usefulness of screening depends on how early the cancer can be diagnosed and how many deaths can be prevented by early treatment as compared with later symptom-prompted diagnosis and treatment. To fully understand current discussions on the evidence for lung cancer screening, key concepts of screening and definitions are needed.Screening for a cancer should be considered when the cancer is significant in terms of incidence and mortality, treatment of early-stage disease is better than treatment of late-stage disease, and there is a test that provides an earlier diagnosis-lead time-rather than a later, symptomprompted diagnosis [1,2].Lung cancer kills more people than any other cancer worldwide. In the U.S. it kills more pe...

show abstract

“…15,[19][20][21] The poor long-term prognosis is due to the development of local and distant recurrences. In fact, distant disease is the most common pattern of failure in stage I NSCLC, and 6-11% of local recurrence versus 23-30% of distant metastases is reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long‐term survival in a randomized study

Roselli

Mariotti

Ferroni

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Although surgical resection is considered the adequate treatment in early stages of nonsmall cell lung cancer, long-term survival is not satisfactory and recurrence rate is high. We previously showed that postoperative chemotherapy at stage IB reduces recurrences and prolongs overall survival. We extended size and observation period of the study sample and performed a separate analysis for minimally resected patients. The trial was designed as a randomized, 2-armed study with postoperative adjuvant chemotherapy versus surgery alone as control group. All patients had stage IB disease (pT2N0) assessed after a radical surgical procedure (defined as anatomical or minimal). Chemotherapy consisted of cisplatin (100 mg/m 2 day 1) and etoposide (120 mg/m 2 days 1-3) for 6 cycles. The primary endpoint was overall survival; secondary endpoint was disease-free survival (DFS). One hundred and forty patients entered the study: 70 were assigned to the adjuvant chemotherapy group and 70 to the control group. Groups were homogeneous for conventional risk factors. There was no clinically significant morbidity associated to chemotherapy. Patients were followed for a mean period of 40.31 6 30.86 months. A significant difference in overall (p 5 0.02) and disease-free (p 5 0.0001) survival was observed between patients undergoing adjuvant chemotherapy vs. control group. Adjuvant chemotherapy significantly improved both overall (p 5 0.02) and DFS (p 5 0.003) of anatomically resected patients, but only the DFS (p 5 0.02) of minimally resected patients. Our results confirm that adjuvant chemotherapy may have a real impact on long-term survival in patients with stage IB nonsmall cell lung cancer being this effect especially evident for those anatomically resected. ' 2006 Wiley-Liss, Inc.Key words: adjuvant chemotherapy; NSCLC IB; long-term survival Radical surgical resection is considered the adequate treatment in providing survival benefits for early nonsmall cell lung cancer (NSCLC), especially for those patients without lymph node involvement.1 A variety of surgical procedures exist (e.g. standard, atypical, parenchyma-sparing or extended procedures) but all aim at the resection of NSCLC oncologically complete. Notwithstanding, long-term survival is not satisfactory and the recurrence rate is quite high 2-4 due to the presence of micrometastases 5-7 not detectable by conventional diagnostic procedures and, therefore, not eradicable by surgery. To prevent this occurrence, postoperative adjuvant systemic therapy was proposed even in the case of surgical procedures deemed radical. 8,9 A recent meta-analysis of all randomized trials with accrual from January 1965 to December 1991 showed that the absolute risk of death was reduced by 3% at 2 years and 5% at 5 years for patients who were treated with postoperative cisplatin-containing regimens.10 According to these evidences some institutions, 8,9,11,12 proposed adjuvant chemotherapy even after presumed radical surgery at stage I, despite discordant results presented by another multicentr...

show abstract

Prognostic assessment of 1310 patients with non–small-cell lung cancer who underwent complete resection from 1980 to 1993

Cited by 107 publications

References 13 publications

Unification of T2a and T2b Tumors to T2 Tumors in Non-Small Cell Lung Cancer Staging

Unification of T2a and T2b Tumors to T2 Tumors in Non-Small Cell Lung Cancer Staging

CT Screening for Lung Cancer: Update 2007

Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long‐term survival in a randomized study

Contact Info

Product

Resources

About